Celltrion's 'Rekkirona' Selected as a Promising COVID-19 Treatment in Europe
[Asia Economy Reporter Seo So-jeong] Celltrion announced on the 30th that its COVID-19 antibody treatment 'Rekkirona' has been selected by the European Commission (EC) as a promising COVID-19 treatment.
The EC selected and announced five promising COVID-19 treatments aimed at treating patients across the European region. This is the first time the EC has selected and announced promising treatments related to COVID-19.
The EC selected a total of five promising treatments, including Celltrion's Rekkirona, four antibody treatments currently undergoing rolling review (pre-authorization review process) at the European Medicines Agency (EMA), and one immunosuppressant currently on the market.
According to Celltrion, the EC views the selection of these promising treatments in the context of the COVID-19 virus not disappearing despite rapid vaccine rollout, highlighting the need for safe and effective treatments. The EC plans to further identify promising treatments, approve at least three treatments available for use throughout Europe by October, and secure a total of five treatments by the end of the year.
Along with three other promising antibody treatments, Celltrion is currently undergoing rolling review at the EMA, and has recently submitted the global Phase 3 clinical trial results of Rekkirona, which confirmed safety and efficacy, to the EMA.
Celltrion is accelerating efforts to obtain approval for Rekkirona by securing positive animal efficacy test results against various COVID-19 variants and submitting them to regulatory agencies worldwide.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- 'Still Hesitant? If You're Wondering Whether KOSPI Will Rise, This Is the Number You Must Watch [Weekend Money]'
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Samsung Life Stock Depends More on Samsung Electronics Than Insurance? [Weekend Money]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
A Celltrion official stated, "The EC's selection of promising treatments is the result of objective and scientific judgment by European Union experts. We will focus on the ongoing EMA rolling review to ensure that Rekkirona is utilized as a COVID-19 treatment across Europe, and we will dedicate ourselves to developing appropriate treatments capable of responding to currently spreading variants."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
